Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Equity Ratio (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Equity Ratio for 11 consecutive years, with 0.85 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio rose 23.91% to 0.85 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.85, a 23.91% increase, with the full-year FY2024 number at 0.84, up 2.71% from a year prior.
  • Equity Ratio was 0.85 for Q3 2025 at Marker Therapeutics, up from 0.71 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.87 in Q2 2023 to a low of 0.54 in Q2 2022.
  • A 5-year average of 0.74 and a median of 0.79 in 2021 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: tumbled 31.84% in 2022, then soared 61.85% in 2023.
  • Marker Therapeutics' Equity Ratio stood at 0.65 in 2021, then fell by 11.79% to 0.57 in 2022, then skyrocketed by 44.09% to 0.82 in 2023, then grew by 2.71% to 0.84 in 2024, then grew by 0.4% to 0.85 in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Equity Ratio are 0.85 (Q3 2025), 0.71 (Q2 2025), and 0.85 (Q1 2025).